[Research Progress of Non-coding RNA in Multiple Myeloma with Heart Disease---Review]
Man-Ya Yu1, Su-Mei Li1, Xing Cui2
1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine,Jinan 250011, Shandong Province, China.
Abstract:
Some non-coding RNAs (ncRNA), as functional RNA molecules, lack potential to encode proteins, but can affect gene expression and disease progression through a variety of mechanisms. In multiple myeloma (MM), cardiovascular disease is one of the most common complications, which may be related to a variety of factors, including patient's own factors, disease-related factors, drug factors, etc. Non-coding RNA is considered to be an important regulator of cardiovascular event risk factors and cell function, and an important candidate target for improving the condition and prognostic assessment. This article briefly summarized the role of non-coding RNA in cardiac amyloidosis caused by MM, damage to the heart by inflammatory factors, and heart disease caused by chemotherapy drugs in recent years.
Insights
Non-coding RNAs (ncRNA) play a key role in multiple myeloma (MM) complications, particularly cardiovascular disease. Understanding ncRNA
Area of Science:
- Molecular Biology
- Genetics
- Cardiology
Background:
- Non-coding RNAs (ncRNAs) are functional RNA molecules that do not encode proteins but regulate gene expression.
- Cardiovascular disease is a common complication in multiple myeloma (MM), influenced by various factors.
- ncRNAs are implicated as regulators of cardiovascular risk factors and cellular functions.
Purpose of the Study:
- To summarize the recent roles of ncRNAs in cardiovascular complications associated with multiple myeloma.
- To explore ncRNA involvement in MM-related cardiac amyloidosis, inflammation-induced heart damage, and chemotherapy-induced cardiotoxicity.
Main Methods:
- Literature review of recent studies on non-coding RNAs and cardiovascular disease in multiple myeloma.
- Analysis of ncRNA mechanisms in cardiac amyloidosis, inflammatory heart damage, and drug-induced cardiotoxicity.
Main Results:
- ncRNAs are emerging as critical regulators in the pathogenesis of MM-related cardiovascular complications.
- Specific ncRNAs are linked to cardiac amyloidosis, inflammation, and cardiotoxicity from MM treatments.
- ncRNAs represent potential therapeutic targets and prognostic biomarkers for cardiovascular events in MM patients.
Conclusions:
- Non-coding RNAs are significantly involved in the development of cardiovascular complications in multiple myeloma.
- Targeting ncRNAs may offer novel strategies for managing and predicting cardiovascular risk in MM patients.
- Further research into ncRNA functions can improve patient outcomes and prognostic assessments.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:13Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription factors...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy